Qiagen N.v. · NYSE:QGEN
Qiagen — 15th German Corporate Conference 2016 (Kepler Cheuvreux)
19 slides from Qiagen's conference presentation, Jan 18, 2016
Slide 1: Making improvements in life possible
Making improvements in life possible Roland Sackers Chief Financial Officer 15th German Corporate Conference, January 2016 Sample to Insight
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1
Slide 3: QIAGEN at a glance
QIAGEN at a glance 2014 sales ~$1.35 billion Customers >500,000 Global reach >35 countries Employees ~4,500 Share listings NASDAQ / Frankfurt Headquarters Netherlands We help customers gain insights to improve healthcare and advance science Sample to Insight 15th German Corporate Conference, January
Slide 4: World leader in molecular testing solutions that enable valuable insights
SAMPLE TO INSIGHT SOLUTIONS Sample Technologies Assay Technologies Bioinformatics Automation VALUABLE BIOLOGICAL MOLECULAR SAMPLE INSIGHTS World leader in molecular testing solutions that enable valuable insights Sample to Insight 15th German Corporate Conference, January 2016 4
Slide 5: Addressing the needs of >500,000 customers worldwide
QIAGEN sales by product group As % of 2014 net sales: $1.35 billion 2014 distribution Molecular Diagnostics Consumables ~50% (incl. bioinformatics) ~87% Applied Testing ~8% Pharma ~19% ~13% Academia Instruments and automation solutions ~23% Addressing the needs of >500,000 customers worldwide Sample
Slide 6: Building leadership across Life Sciences and Molecular Diagnostics
QIAGEN sales by customer class $1.35 bn $1.25 bn $1.09 bn Differentiated 39% portfolio for 33% Molecular clinical healthcare $0.9 bn 26% Diagnostics 23% 11% HPV 16% 22% (12%) (6%) (U.S. share) (17%) 24% 8% 8% Applied Testing (19%) 6% 6% 19% 19% Pharma 21% Life 21% Sciences 24% 23% Academia 26% 25% 2
Slide 7: Transforming QIAGEN to leadership in Molecular Diagnostics and Life Sciences
Molecular Applied Adjusted net sales overview: 2010-2014 Diagnostics Testing Pharma Academia (In $ billions, as percentage of sales) QIAsymphony $1.35 bn $1.25 bn Personalized Healthcare (PHC) $1.09 bn ~30% ~22% ~15% QuantiFERON-TB Bioinformatics ~68% ~65% ~64% GeneReader NGS System QIAseq universal
Slide 8: QIAsymphony: Driving molecular testing dissemination
QIAsymphony: Driving molecular testing dissemination Sample to Insight 15th German Corporate Conference, January 2016 8
Slide 9: Personalized Healthcare: Pioneer in companion diagnostics
Personalized Healthcare: Pioneer in companion diagnostics Sample to Insight 15th German Corporate Conference, January 2016 9
Slide 10: QuantiFERON-TB: At the forefront in the war against tuberculosis
QuantiFERON-TB: At the forefront in the war against tuberculosis Sample to Insight 15th German Corporate Conference, January 2016 10
Slide 11: Bioinformatics: Analyzing complex data beyond human comprehension
Bioinformatics: Analyzing complex data beyond human comprehension Sample to Insight 15th German Corporate Conference, January 2016 11
Slide 12: Next-gen sequencing: Ambition to drive benefits into clinical healthcare
Next-gen sequencing: Ambition to drive benefits into clinical healthcare Sample to Insight 15th German Corporate Conference, January 2016 12
Slide 13: The challenge The demand
The challenge The demand Fragmented Analyzing and Efficient Complete High costs Cost-effective workflows interpreting data to operate workflow Many barriers hampering NGS utilization Labs have consistent views on NGS demands The world’s first complete Sample to Insight NGS solution for actionable re
Slide 14: The world's first complete Sample to Insight NGS solution for actionable results
Sample type Unique Reliable Powerful analysis breadth automation results and interpretation GeneReader NGS System 1. First complete NGS workflow 2. Actionable insights Seamless integration Reports linked to proven gene panel Single vendor for full solution Highest-quality bioinformatics plat
Slide 15: 2015 results: Progress on many initiatives to create new growth wave
Preliminary Q4 2015 adjusted net sales Preliminary 2015 adjusted net sales (In $ millions) (In $ millions) ~ +3% CER ~1,280 m Companion diagnostics Growth driver expansion partner revenues Instrument sales Improving Life Sciences $1,346 m ~ +3% CER ~$348 m $360.8 m ~-3 p.p. ~+6% CER. ~-1 p.p. ~+4% C
Slide 16: Selected QIAGEN portfolio areas
Selected QIAGEN portfolio areas 2015 2016 results outlook Growth drivers: Adjusted net sales: QIAsymphony ~+6% CER / - 2 p.p. FX QuantiFERON Adjusted diluted EPS: CER growth with sales / - 2 p.p. FX Personalized Q4: CDx partner Healthcare milestone timing Key investment areas
Slide 17: Delivering free cash flow gains and improving balance sheet efficiency
Free cash flow trends Leverage ratio: Net debt / adjusted EBITDA(1) 3.5 3.3 $163 m 3.0 $149 m 2.5 2.2 $121 m 2.0 1.5 1.5 1.2 1.1 0.9 0.9 1.0 0.5 0.4 0.2 0.0 9M 2013 9M 2014 9M 2015 - 0.1 -0.5 2006 2006 2008 2008 2010 2010 2012 2012 2014 Q3 2014 Q3 2015 2015 Delivering free cash flow gains and improv
Slide 18: Disciplined capital allocation
DISCIPLINED CAPITAL ALLOCATION Reinvest for organic growth Increase returns Targeted M&A / licensing Strengthen our premium > $500 m returned to Continuing our strategy Sample to Insight portfolio shareholders (2013-2015) Novel technologies Repurchases of shares Molecular test content an
Slide 19: Summary
Summary Expanding leadership in Sample to Insight solutions Leading positions in the most exciting areas of molecular diagnostics and life sciences Delivering growth during transformation 2016: Moving into a faster growth phase Sample to Insight 15th German Corporate Conference, January 2016 19
Qiagen — 15th German Corporate Conference 2016 (Kepler Cheuvreux) on 6ix